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http://ccforum.com/content/18/6/649RESEARCH Open AccessIntravenous immunoglobulin for severe sepsis
and septic shock: clinical effectiveness,
cost-effectiveness and value of a further
randomised controlled trial
Marta O Soares1*, Nicky J Welton2, David A Harrison3, Piia Peura1, Manu Shankar-Hari4, Sheila E Harvey3,
Jason Madan5, Anthony E Ades2, Kathryn M Rowan3 and Stephen J Palmer1Abstract
Introduction: Prior to investing in a large, multicentre randomised controlled trial (RCT), the National Institute for
Health Research in the UK called for an evaluation of the feasibility and value for money of undertaking a trial on
intravenous immunoglobulin (IVIG) as an adjuvant therapy for severe sepsis/septic shock.
Methods: In response to this call, this study assessed the clinical and cost-effectiveness of IVIG (using a decision model),
and evaluated the value of conducting an RCT (using expected value of information (EVI) analysis). The evidence
informing such assessments was obtained through a series of systematic reviews and meta-analyses. Further primary
data analyses were also undertaken using the Intensive Care National Audit & Research Centre Case Mix Programme
Database, and a Scottish Intensive Care Society research study.
Results: We found a large degree of statistical heterogeneity in the clinical evidence on treatment effect, and the source
of such heterogeneity was unclear. The incremental cost-effectiveness ratio of IVIG is within the borderline region of
estimates considered to represent value for money, but results appear highly sensitive to the choice of model used for
clinical effectiveness. This was also the case with EVI estimates, with maximum payoffs from conducting a further clinical
trial between £137 and £1,011 million.
Conclusions: Our analyses suggest that there is a need for a further RCT. Results on the value of conducting such
research, however, were sensitive to the clinical effectiveness model used, reflecting the high level of heterogeneity in
the evidence base.Introduction
Sepsis is a clinical syndrome defined by the presence of
both infection and a systemic inflammatory response;
sepsis is defined as severe when associated with, or
complicated by, organ dysfunction [1]. Severe sepsis may
induce septic shock, defined as hypotension persisting
despite adequate fluid resuscitation [2]. There is evidence
indicating an increasing incidence of severe sepsis treated
in critical care in England, Wales and Northern Ireland,
rising from 50 to 70 cases per 100,000 population per year* Correspondence: marta.soares@york.ac.uk
1Centre for Health Economics, University of York, Heslington, York, YO10 5DD, UK
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reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.between 1995 and 2005 - these cases being associated
with approximately 31,000 episodes of severe sepsis
and 15,000 in-hospital deaths per year [3]. Being a
serious, life-threatening condition, severe sepsis is expected
to be associated with substantial healthcare costs and
a significant impact on quality of life.
Intravenous immunoglobulin (IVIG) is a scarce blood
product derived from human donor blood; it is currently
subject to a Demand Management Programme by the
United Kingdom (UK) Department of Health [4]. This
product has been proposed as an adjuvant therapy for
severe sepsis/septic shock since the 1980s. However, the
mechanisms of action of IVIG are complex and are not yet
fully understood. Despite this, a number of (predominantlyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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conducted, and numerous systematic reviews and
meta-analyses have been undertaken to synthesise
their findings [5-8]. As a result of the heterogeneity
across studies and the inconsistencies in their results,
the majority conclude that there is currently insufficient
evidence to recommend IVIG as an adjuvant therapy and
that more evidence, in the form of a large, well-conducted
RCT, is required.
Prior to investing in a large, multicentre RCT, the
Health Technology Assessment (HTA) Programme of
the National Institute for Health Research in the UK
called for an evaluation of the feasibility and value for
money of undertaking such a trial (that is, whether or
not the costs of undertaking the trial are outweighed by
the potential benefit of the resulting information).
The aim of this manuscript is to report our findings
in response to this call by assessing the clinical and
cost-effectiveness of IVIG in severe sepsis/septic shock in
adults, and evaluating the value of conducting a large,
multicentre RCT using an expected value of information
(EVI) analysis. EVI offers a methodological framework
that explicitly considers the uncertainty surrounding
the decision by a healthcare system to adopt a health
technology and values the additional information, which
may be generated by further research, in a way that is
consistent with the objectives and resource constraints of
heathcare provision [9].
A full technical report of this research is published
elsewhere [10]. Here, we provide a summary of the
evaluation of clinical effectiveness, cost-effectiveness,
and value of information of IVIG in critically ill adults
with severe sepsis/septic shock, undertaken to inform
the UK policy context. We discuss the implications
arising from this policy-driven evidence review.
Methods
We conducted a series of formal systematic reviews and
undertook additional primary data analysis to develop
and populate a decision analytic model. Details of
each review and data sources are presented in the full
technical report [10]. The decision model evaluated the
cost-effectiveness of IVIG as an adjunctive treatment to
standard care for the management of adults with severe
sepsis (we have used the term severe sepsis in this
manuscript to include septic shock). The base-case
population in the model reflected the baseline characteris-
tics of the severe sepsis population in the Intensive Care
National Audit & Research Centre (ICNARC) Case Mix
Programme Database (CMPD), a high-quality clinical
database of admissions to adult general (mixed medical/
surgical) critical care units in the UK, considered to
be more representative of current UK National Health
Service (NHS) practice than the populations recruitedinto RCTs. We used data for the years 2007 to 2009,
corresponding to a sample of 26,249 patients.
The decision model evaluated costs from the perspective
of the NHS and Personal Social Services (PSS), and
expressed these in British pounds sterling at a 2009 price
base. Outcomes were expressed in quality-adjusted life
years (QALYs). Both costs and outcomes were discounted
using a 3.5% annual discount rate, in line with current
guidelines [11]. The model was probabilistic, that is,
uncertainty over the input parameters was propagated
through the model in such a way that the results of
the analysis could be presented with their associated
uncertainty [12]. The expected costs and QALYs for IVIG
and standard care (SC) were estimated and compared
using incremental cost-effectiveness ratios (ICERs) that
represent the incremental cost per additional QALY. The
ICER was compared against thresholds used to establish
value for money in the NHS (currently in the region of
£20,000 to £30,000 per QALY) [11].
The probabilistic analysis also provided a formal
approach to quantifying the consequences associated
with the uncertainty surrounding the model results,
which were then used to inform the EVI analyses.
The maximum amount the NHS should be willing to
invest to reduce uncertainty in the decision can be
informed by the expected value of perfect information
(EVPI) [13,14]. The EVPI evaluates the expected cost of
current uncertainty by accounting both for the probability
that a decision based on existing evidence is wrong and
for the magnitude of the consequences of making the
wrong decisions. EVPI can be expressed at a popula-
tion level based on the size of the population (yearly
incidence = 33,160) and the number of years research is
assumed useful (10 years). EVPI can also be estimated for
individual parameters (or for groups of parameters)
contained in the model, termed partial EVPI or EVPPI.
Five groups of uncertain parameters were considered: i)
baseline mortality during the initial acute hospitalisation
with SC; ii) clinical effectiveness of IVIG; iii) long-term
mortality estimates for survivors of severe sepsis; iv)
long-term costs for survivors of severe sepsis; v) quality of
life for survivors of severe sepsis. The groups of parameters
also reflect potentially different research designs. For
example, while an RCT would ideally be required to
further inform the clinical effectiveness of IVIG, evidence
on the other parameters could be generated using record
linkage of existing databases.
The EVPI estimates set an upper limit on the returns to
further research. However, to fully inform the research
decision, the most efficient research design also needs to
be established, for example, the type of study, the optimal
sample size, the appropriate duration of follow-up and
appropriate end points. The same framework of analyses
can be extended to establish the expected value of sample
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obtain the societal payoff to the proposed research, the
population EVSI needs to be compared with the costs of
sampling: the difference between the EVSI and the costs
of sampling gives the expected net benefit of sampling
(ENBS). The ENBS provides a necessary and sufficient
condition for deciding to conduct more research that is, if
the ENBS is greater than zero for any sample size then the
benefits of gathering the sample information exceed
the costs, and further research is potentially justified. The
ENBS also provides a framework for the efficient design of
the clinical trial, where the optimal sample size, n*, for the
proposed trial is where the ENBS reaches its maximum.
This optimal sample size thus indicates how many
patients should be enrolled for the trial to provide
the highest payoff.
All stages of the work were informed through discussions
with an expert clinical advisory group who provided
feedback on specific aspects of the analyses including
the model structure, inputs and assumptions.
Decision model structure
A simplified schematic of the structure of the decision
model is presented in Figure 1. The model evaluated the
lifetime prognosis of severe sepsis in order to capture
the longer-term costs and consequences associated with
the natural history in the absence of IVIG. The model
structure considered two related elements reflecting
short- and long-term consequences:
i. short-term: the short-term consequences of the
initial severe sepsis episode reflected the initial
acute hospitalisation period (acute hospital and
critical care) and related to the probability of
surviving the initial acute hospitalisation. Baseline
data from the CMPD were used to estimate the risk
of acute hospital mortality associated with SC and
the results of a systematic review of the clinicalFigure 1 Model schematic.effectiveness of IVIG were applied to estimate the
risk of acute hospital mortality associated with IVIG.
ii. longer-term: conditional on having survived the
initial acute hospitalisation, a Markov structure
was used to characterise the long-term prognosis over
the remainder of a patient’s lifetime. Such a model
represents disease progression by defining important
mutually exclusive events/health states and
characterising how patients may move between states
over regular time intervals. Here, we used a simple
structure to represent the possibility of patients being
alive or dead (a survival model). Annual cycles were
employed to reflect the annual probability of death for
each year after the initial severe sepsis episode.
Duration of stay alive or transition to death can be
associated with a quality of life score and with costs
incurred, allowing for long-term QALYs and costs to
be evaluated. If IVIG reduces the risk of mortality
during the initial acute hospitalisation period, then the
use of this longer-term model will allow differences in
long-term costs and QALYs to be translated.
The model was developed in the statistical programming
package R [15].
Clinical effectiveness of IVIG
Evidence on the effectiveness of IVIG was sought and
used to inform the decision model and further analyses.
A systematic review of the literature was conducted to
inform the effect of IVIG in severe sepsis on all-cause
mortality during the initial acute hospitalisation. Full details
of the methods of the systematic review are reported in the
full technical report [10]. In summary, RCTs within a
critical care setting that compared any standard polyclonal
IVIG or immunoglobulin M-enriched polyclonal IVIG
(IVIGAM) with either no intervention, placebo (usually
albumin) or another standard polyclonal IVIG or IVIGAM
preparation were considered eligible for inclusion.
Studies were included if the majority of patients were
aged ≥18 years and clinical judgement deemed the
population studied to have severe sepsis.
The primary outcome measure extracted was all-cause
mortality, summarised on the odds ratio (OR) scale.
Fixed- and random-effects meta-analyses were fitted using
inverse variance weights. Heterogeneity was assessed using
I2, and Cochrans Q test. Stata, version 11.0 (StataCorp LP,
College Station, TX, USA), was used.
Heterogeneity was further explored comparing model fit
from meta-regressions, estimated through Bayesian [16]
Markov chain Monte Carlo simulation [17] using WinBUGS
version 1.4.3 (MRC Biostatistics Unit, Cambridge, UK)
[18,19]. More detail on the use of Bayesian methods in
meta-analysis and evidence synthesis can be found in
Sutton and Abrams [20], and in Spiegelhalter et al. [21].
Soares et al. Critical Care 2014, 18:649 Page 4 of 13
http://ccforum.com/content/18/6/649Results are presented using means and 95% credible
intervals, 95%CrI (the Bayesian equivalent to confidence
intervals) [20]. The posterior mean residual deviance
(Dres) was used to measure model fit and the deviance
information criterion (DIC), a composite measure of model
fit and model complexity, was used to choose between
competing models [22]. For the random-effects models, the
posterior mean of the between-study standard deviation
(SD) parameter (τ) was used to investigate the impact of
the inclusion of the covariates on explaining (reducing)
heterogeneity. Meta-regressions aimed to: i) identify key
covariates responsible for heterogeneity; ii) consider more
complex treatment models that compared different types
and preparations of IVIG; and iii) adjust for potential
confounding by considering combinations of covariates.
The covariates evaluated related to: characteristics of
treatments such as type and dose of IVIG; features of
study design related to, or a proxy for, study quality
(for example Jadad score - a composite measure ranging
from 0 to 5 where 5 indicates best quality and sample size);
setting; acute severity of disease; and follow-up period. Key
covariates that explained some of the heterogeneity using
model fit statistics (Dres, DIC and τ) were identified. In
addition, combinations of key potential covariates were
explored to identify which of the covariates best explained
the heterogeneity, after having adjusted for other covariates.
Other treatment models were also explored, in which the
type of IVIG preparation and type of control were not
grouped together. All treatment and covariate models were
compared using the model fit statistics (Dres, DIC and τ).
Results were reported for the best-fitting, competing
models.
Other inputs of the decision model
Baseline event rates for standard care (initial acute
hospitalisation)
Data from the CMPD (n = 26,249) were used to inform
the baseline risk of acute hospital mortality applied to
SC during the initial hospitalisation. Mortality risk was
estimated by conditioning on characteristics of patients
and the severity of illness at presentation: age and
gender; Acute Physiology and Chronic Health Evaluation II
(APACHE II) score; ICNARC physiology score and number
of dysfunctional organ systems. Logistic regressions (robust
standard errors (SEs) adjusting for clustering on critical
care unit) were used.
Longer-term survival
We undertook additional primary data analysis to inform
the longer-term survival estimates for severe sepsis survivors
based on a cohort of 345 subjects from the Scottish
Intensive Care Society (SICS) prospective, observational,
multicentre, epidemiological study of severe sepsis [23].
Only patients (n = 271) for whom organ system dysfunctionwas clearly reported were selected. Average follow-up for
survival was 787 days (range 0 to 2,062) days.
Parametric survival analyses were undertaken to estimate
longer-term mortality (goodness of fit was assessed using
Akaike information criterion (AIC) statistics). Three
separate models were fitted including additional covariates
for: age; APACHE II score at admission; and organ system
dysfunction. The covariates were included to adjust for
potential imbalances between the baseline characteristics
from the CMPD (used to estimate short-term mortality)
and the SICS study cohort. Also, these covariates
allowed for consideration of subgroup-specific estimates
for longer-term survival.
Resource use, unit costs and health-related quality of life
The length of stay (LOS) during the index severe sepsis
episode (from the CMPD) was used to cost the acute
hospital stay. Unit costs were derived from national
databases. A summary of the information used is pre-
sented in Table 1 and further details of the results of two
separate literature reviews, on health-related quality of life
(HRQoL) and resource use, are available in the full
technical report [10].
Results
Table 1 provides a summary of the model input parameters
used (both from the systematic reviews and from the
primary data analysis) to inform the cost-effectiveness
of IVIG.
Clinical effectiveness of IVIG
Seventeen studies were identified that met the inclusion
criteria with a large degree of heterogeneity in treatment
effect between studies [27-40]. Figure 2 presents a funnel
plot of the SE of the effect size (log-OR) plotted against
study effect size (OR on the log scale). The asymmetry
suggests there may be publication bias with this evidence
and further exploratory analyses were conducted.
Unadjusted fixed- and random-effects meta-analyses
were implemented, initially comparing two treatment
groupings (IVIG or IVIGAM vs. albumin/no treatment)
(Figure 3). Given the heterogeneity (I2 = 46.9%), a random-
effects model fitted the data well while the fixed-effect
model showed substantial lack of fit. The pooled OR from
the random-effects model was 0.47 (95% CI 0.32 to 0.69),
showing a stronger effect than the fixed-effect model
(pooled OR= 0.68; 95% CI 0.54 to 0.84).
From the meta-regression analyses, key covariates
appearing to explain the existing heterogeneity between
studies were: dosing regimen (duration of treatment
(days), daily dose (g kg−1 day−1), volume (ml kg−1 day−1));
and study quality (that is use of albumin as control - as
a proxy for proper blinding to treatment, Jadad score,
publication date, and a measure of sample size; 1/ N).
Table 1 Inputs of the decision model for the evaluation of IVIG for severe sepsis/septic shock: parameter values and
uncertainty over parameter values
Parameter Source Base case Notes on scenario
analyses undertaken
Notes on subgroup analyses
Cohort characteristics
Mean age of a severe sepsis patient
at admission to hospital
CMPD 63 years old Same as base case Assumed to vary in subgroups
defined using age. Sourced from
ICNARC database
Proportion of males in a severe sepsis
population at admission to hospital
CMPD 0.53 Same as base case Assumed to vary in subgroups
defined using gender. Sourced
from CMPD
Short-term outcomes (ST)
Probability of dying in hospital when SC
is used in the treatment of severe sepsis
(baseline risk)
CMPD 40.6%, 95%
CI (40%, 41.2%)
Same as base case Assumed to vary per subgroup
(all). Sourced from CMPD
Odds ratio, when IVIG is used to
complement SC in the treatment of
severe sepsis (based on Model M1)
Evidence synthesis
(‘Clinical effectiveness
of IVIG’)
0.75 , 95%
CI (0.58, 0.96)
Alternative models
tested; see Table 2
Same as base case
Longer-term outcomes (LT)
Age specific probability of dying in yearly
intervals, conditional on patients having
survived up to the start of the year.
Cuthbertson
database and
general population
life tables 2010
Figure 4. Varies
with time.
(1) time horizon Assumed to vary for subgroups
defined using age and APACHE II
score. Sourced from CMPD(2) time points at
which patients
reverted to survival
of general population
Cost-related parameters
Costs of overall IVIG therapy Non-stochastic, BNF £5,539.05 Same as base case Same as base case
Costs of SC, when only SC is used in
the treatment of severe sepsis
Non-stochastic, £0 Same as base case Same as base case
LOS in ICU for patients remaining alive
until discharge from hospital
CMPD 8.48 (SE = 0.086) Same as base case Assumed to vary for all
subgroups. Sourced from CMPD
LOS in ICU for patients dying in hospital CMPD 7.40 (SE = 0.108) Same as base case Assumed to vary for all
subgroups. Sourced from CMPD
Costs associated to a day in ICU for a
patient with severe sepsis
Non-stochastic,
reference costs [24]
£1,393 Same as base case Same as base case
Overall hospital LOS for patients remaining
alive until discharge from hospital
CMPD 21.29 (SE = 0.292) Same as base case Assumed to vary for all
subgroups. Sourced from CMPD
Overall hospital LOS for patients dying in
hospital
CMPD 39.07 (SE = 0.325) Same as base case Assumed to vary for all
subgroups. Sourced from CMPD
Costs associated to a day in wards
other than ICU for a patient with a
severe sepsis episode
Non-stochastic,
reference costs [24]
£196 Same as base case Same as base case
Costs incurred between year t-1 and
year t after hospital discharge
Manns [25] t = 1: £13,654 and
t >1: £4,466.5/year
(1) ± 50% of Manns’
estimates
Same as base case
(2) average annual per
capital NHS cost for the
general population
Utilities
In-hospital HRQoL weight associated
to severe sepsis patients
Drabinsky [26] 0.53 Same as base case Same as base case
HRQoL weight associated to severe
sepsis patients at year t
Cuthbertson database,
Drabinsky [26]
t = 1: 0.62 and
t >1: 0.6833
Same as base case Same as base case
See NIHR HTA full technical report [10] for a comprehensive reporting of parameter values used to inform the decision model, including those used in subgroup
analyses. IVIG, intravenous immunoglobulin; CMPD, Case Mix Programme Database; ICNARC, Intensive Care National Audit & Research Centre; CI, confidence interval;
BNF, British National Formulary; SC, standard care; APACHE II, Acute Physiology and Chronic Health Evaluation II; LOS, length of stay; HRQoL, health-related quality of life.
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Figure 2 Evidence on the clinical effectiveness of IVIG for severe sepsis (and septic shock): publication bias - funnel plot (with pseudo
95% confidence limits) for mortality of IVIG and IVGAM versus control. IVIG, intravenous immunoglobulin; IVIGAM, immunoglobulin
M-enriched polyclonal IVIG.
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heterogeneity in treatment effect across the studies.
Further detail on these analyses is presented in the full
technical report [10].
Across all the models considered [10], the best-fitting
model assessed three treatments: IVIG/IVIGAM vs.
albumin vs. no treatment and included duration of
IVIG therapy as a treatment effect-modifying covariate.
Results are reported for the most commonly used
duration of therapy reported: three days (model M1 in
Table 2). The OR for IVIG/IVIGAM vs. albumin was
estimated at 0.75 (with a 95% CrI of 0.58 to 0.96) indicating
a reduction in the odds of all-cause mortality for patients
with severe sepsis compared with albumin.
Discussions with the expert clinical advisory group
highlighted that there was no clear clinical rationale
why duration of treatment would affect treatment
effectiveness. For this reason, random-effects models
with solely study quality covariates were also considered.
The heterogeneity that can be explained with the dosing
regimen covariates was left unexplained in these models,
reflecting a belief that these covariates were a proxy for
other, unmeasured, differences between the included
studies. The results of a range of alternative models
are presented in Table 2 (Models M2 to M4b).
When the heterogeneity explained by duration of IVIG
therapy in M1 was treated as unexplained (that is using a
random-effects model, models M2 to M4b), the majorityof results were fairly comparable and still showed a
reduction in the odds of all-cause mortality in patients
with severe sepsis treated with IVIG but the 95% CrI
widened suggesting a larger degree of uncertainty. The
only exception was model M4b, which reported an
increase in the odds of all-cause mortality, albeit with
very wide credible intervals. However, some caution should
be applied to this result since it involves extrapolation
beyond the available data. In the absence of a single
best-fitting model that made clinical sense, sensitivity ana-
lyses were subsequently used in the cost-effectiveness
modelling.
Other input parameters to the decision model
Model input parameters and uncertainty around their
estimates are described in Table 1 (and, in greater detail,
in the full technical report [10]). Briefly, the probability
of dying during the initial hospitalisation was estimated
from the CMPD to be 40.6% (95% CI 40.0%, 41.2%).
With respect to the evidence on longer-term mortality,
we initially investigated the plausibility of the different
parametric predictions beyond the five years of observed
data by comparing these to age-adjusted estimates from
the general population (Figure 4a). It was considered
implausible that the longer-term mortality estimates
for severe sepsis patients would become lower than that
for the general population. Consequently, in the model,
we further assumed that the probability of mortality would
a) 
b) 
Overall  (I-squared = 46.9%, p = 0.017)
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NOTE: Weights are from random effects analysis
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Figure 3 Evidence on the clinical effectiveness of IVIG for severe sepsis (and septic shock): Forest plots for (a) fixed-effects model using
inverse variance weights, and (b) random-effects model using inverse variance weights. Both evaluate IVIG and IVIGAM treatments versus
control. IVIG, intravenous immunoglobulin; IVIGAM, immunoglobulin M-enriched polyclonal IVIG.
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Table 2 Evidence on the clinical effectiveness of IVIG for severe sepsis/septic shock: estimates from the best-fitting
models for the synthesis of evidence
Model for the synthesis of clinical effectiveness evidence Odds ratio (95% CrI)
M1: Fixed-effect model considering three treatments: IVIG/IVIGAM vs. albumin vs. no treatment, with covariate on duration
of IVIG therapy. Relative effectiveness estimate reported for IVIG/IVIGAM vs. albumin for a duration of therapy of three days.
0.75 (0.58, 0.96)
M2: Random-effects model considering three treatments: IVIG/IVIGAM vs. albumin vs. no treatment, no covariates. Relative
effectiveness estimate reported for IVIG/IVIGAM vs. albumin.
0.68 (0.16, 1.83)
M3: Random-effects model considering two treatments: IVIG/IVIGAM vs. albumin or no treatment, with covariate on Jadad
score. Relative effectiveness estimate reported assuming a Jadad score of 5.
0.83 (0.18, 2.13)
M4a: Random-effects model considering two treatments: IVIG/IVIGAM vs. albumin/no treatment, with covariate representing
1=
ﬃﬃﬃ
N
p
. Relative effectiveness estimate reported assuming a sample size of 339 patients*
0.92 (0.23, 2.10)
M4b: Random-effects model considering two treatments: IVIG or IVIGAM vs. albumin or no treatment, with covariates
representing 1=
ﬃﬃﬃ
N
p
. Relative effectiveness estimate assumes an infinitely large sample size*
1.27 (0.25, 3.17)
*With model M4 two cases were considered: for M4a, the sample size N was set equal to the maximum arm size in the studies in our review - avoiding extrapolation
beyond the dataset; for M4b, sample size was set to infinity; this demonstrates the effect on model estimates of the absence of bias associated with study quality,
here proxied by finite (and small) sample sizes. CrI, credible interval, the Bayesian equivalent to confidence intervals; IVIG, intravenous immunoglobulin; IVIGAM,
immunoglobulin M-enriched polyclonal IVIG.
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http://ccforum.com/content/18/6/649be the maximum of the predicted parametric distributions
and the observed yearly probability of mortality for the
general population (age- and sex-adjusted). The ‘modified’
parametric survival functions are reported in Figure 4b.
The distribution with the best statistical goodness of fit
was the Weibull function, and this was further used in the
decision model [10].
With respect to resource use, we obtained estimates
from the literature of total costs per annum and used
these to describe costs after discharge from the index
acute hospitalization [25]. The evidence used distinguishes
the first year from subsequent years. With respect to
HRQoL weights, we found evidence in the literature that
the quality of life of survivors could be represented by a
value of 0.69; also based on the available literature we
assigned additional decrements to the within acute
hospital period (0.09) and to the first month after
acute hospitalisation (0.06).
Cost-effectiveness of IVIG
Table 3 reports the cost-effectiveness results using the
best-fitting clinical effectiveness model for all-cause
mortality and for each of the alternative models from
the clinical effectiveness review considered within the
sensitivity analyses. The results for the best-fitting model
show that the ICER of IVIG is £20,850 per QALY, which
is within the borderline region of estimates considered
to represent value for money in the NHS. At a threshold
of £20,000 per QALY, the probability that IVIG is
cost-effective is 0.505. As the threshold cost per QALY
increased, the probability that IVIG is cost-effective
increased (that is increasing to 0.789 at a threshold of
£30,000).
For the alternative clinical effectiveness models, the
ICER estimates vary between £16,177 per QALY to IVIG
being dominated by SC alone (that is IVIG being both less
effective and more costly). These results clearly demonstratethat any conclusions regarding the cost-effectiveness of
IVIG appear highly sensitive to the choice of model used
for clinical effectiveness. Furthermore, the level of decision
uncertainty, expressed in terms of the probability that IVIG
is cost-effective, remains high across all these scenarios.
Value of further information
Table 4 presents a summary of the population EVPI esti-
mates based on a cost-effectiveness threshold of £20,000
per QALY. The results demonstrate a considerable range
in the population EVPI estimates depending on the model
applied to estimate the relative clinical effectiveness
of IVIG. As expected, the random-effects model gave
higher EVPI estimates given the additional between-study
heterogeneity that is included. For a time horizon of
10 years, population EVPI varied between approximately
£393 million and £1.4 billion. These results clearly
suggested that further primary research would appear
to be potentially worthwhile given the high cost of
current decision uncertainty across all scenarios.
Figure 5 presents EVPPI estimates for the five groups of
uncertain parameters for each of the clinical effectiveness
models. The EVPPI associated with the relative treatment
effect of IVIG consistently emerged as having significant
influence on the overall decision uncertainty: the lowest
estimate of EVPPI for the relative effect of IVIG was
£173.7 million. The longer-term costs of severe sepsis also
seem to be an important driver, with significant value in
all except one of the scenarios. It should be appreciated
that the costs of undertaking research on parameters
such as quality of life would be significantly lower for
these than for those required to undertake a large,
multicentre RCT.
The population ENBS and the optimal sample size,
n*, for a proposed trial are reported in Table 5 (for a
threshold of £20,000). Calculations assumed the costs
of the trial to be based on a fixed cost component of
Figure 4 Longer-term survival of patients after an acute episode of severe sepsis (or septic shock): comparison of parametric survival
functions (a) and their modified versions (b) to general population. The curves in Figure 3a investigate the plausibility of the different parametric
(Weibull, Exponential and Lognormal) predictions beyond the five years of observed data by comparing these to age-adjusted estimates from the
general population. These show that the longer-term mortality parametric estimates for severe sepsis patients become lower than that for the general
population. This was considered implausible and, consequently, we modified these distributions by further assuming that the probability of mortality
would be the maximum of the predicted parametric distributions and the observed yearly probability of mortality for the general population
(age- and sex-adjusted). The ‘modified’ parametric survival functions are reported in Figure 4b.
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patient recruited (+ £5,500 for patients receiving IVIG).
Across scenarios, the maximum payoff from conducting
this research (the ENBS) varies between £137 and £1,011
million. The optimal sample size always exceeded 800
subjects for each arm.
Discussion
Despite the existence of a large number of RCTs and
numerous previous systematic reviews and meta-analyses
of the relative effectiveness of IVIG, there remains contro-
versy surrounding the value of IVIG as an adjunctive treat-
ment in severe sepsis. Our study is the first to combine a
formal systematic review of clinical effectiveness together
with other epidemiological, resource use and quality of lifedata in order to robustly assess both the cost-effectiveness
of IVIG based on existing evidence as well as the value of
conducting further research.
Within this work, we re-analysed existing relative
effectiveness RCT evidence and conducted a new
meta-analysis, the first to simultaneously allow for
type of IVIG (IVIG or IVIGAM), choice of control
(no treatment or albumin), study quality/publication
bias and other potential covariates. Our results indicated
that treatment with IVIG may be associated with lower
mortality but the evidence base shows a large degree of
heterogeneity between individual studies. Given it was
unclear what was the relevant source of heterogeneity
in the evidence base, alternative clinical effectiveness models
were evaluated.
Table 3 Cost-effectiveness of IVIG for severe sepsis/septic shock using the best-fitting and alternative synthesis models
of effectiveness evidence (see Table 2 for detailed specification of the models)
(Best-fitting model, M1) Fixed-effect model estimate (IVIG/IVIGAM compared with albumin)
considering 3 days duration of IVIG therapy
Probability of being cost-effective for
cost-effectiveness threshold
Treatment Mean cost Mean QALY ICER £20,000/QALY £30,000/QALY
IVIG £54,901 4.35 £20,850 0.505 0.789
Standard care £45,593 3.90 0.495 0.211
(Alternative model M2) Random-effects model estimate (IVIG/IVIGAM compared with albumin)
Treatment Mean cost Mean QALY ICER £20,000/QALY £30,000/QALY
IVIG £57,200 4.62 £16,177 0.597 0.707
Standard care £45,593 3.90 0.403 0,295
(Alternative model M3) Random-effects model (IVIG/IVIGAM compared with albumin/no treatments)
considering Jadad score = 5
Treatment Mean cost Mean QALY ICER £20,000/QALY £30,000/QALY
IVIG £55,238 4.39 £19,968 0.502 0.611
Standard care £45,593 3.90 0.498 0.389
(Alternative model M4a) Random-effects model (IVIG/IVIGAM compared with albumin/no treatment)
considering a sample size of 339
Treatment Mean cost Mean QALY ICER £20,000/QALY £30,000/QALY
IVIG £53,518 4.18 £28,520 0.404 0.514
Standard care £45,593 3.90 0.596 0.486
(Alternative model M4b) Random-effects model (IVIG/IVIGAM compared with albumin/no treatment)
considering a sample size of infinity
Treatment Mean cost Mean QALY ICER £20,000/QALY £30,000/QALY
IVIG £50,024 3.76 Dominated 0.275 0.348
Standard care £45,593 3.90 0.725 0.652
IVIG, intravenous immunoglobulin; IVIGAM, immunoglobulin M-enriched polyclonal IVIG; QALY, quality-adjusted life years; ICER, incremental
cost-effectiveness ratio.
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within the borderline region of estimates considered to
represent value for money in the NHS, but these results are
associated with significant decision uncertainty and appear
highly sensitive to the alternative clinical effectiveness
models applied. Using an expected value of informationTable 4 Value of further research on IVIG for severe sepsis/
septic shock: population EVPI estimates (WTP = £20,000),
according to alternative synthesis models of effectiveness
evidence (see Table 2 for detailed specification of the
models)
Scenarios for alternative
synthesis models of
effectiveness evidence
EVPI per
patient
Population EVPI
(Time horizon = 10 years)
M1 £1,377 £392,994,216
M2 £3,563 £1,017,023,732
M3 £4,791 £1,367,426,550
M4a £3,146 £897,945,285
M4b £2,113 £603,018,958
EVPI evaluates the expected cost of current uncertainty by accounting both
for the probability that a decision based on existing evidence is wrong and for
the magnitude of the consequences of making the wrong decisions. EVPI,
expected value of perfect information.framework, we established the value of collecting further
information. Results show that a study collecting data on
the relative effectiveness of IVIG (in comparison with
standard care) appeared the most efficient research design
to invest in. However, results on the value of conducting
such research were also sensitive to the clinical effectiveness
model used. Given that it was unclear what the clinical
rationale for the effects explored was within each of the
clinical effectiveness models and that the need for a
further RCT exists, designing this study will be complex
when uncertainties exist at this level.
Policy implications
Our study did not find evidence that current guidance
on the use of IVIG should change (that is IVIG should
not be recommended for use in severe sepsis, unless
further evidence becomes available to support its use).
Although the EVI analyses suggested substantial potential
value from a large, multicentre RCT evaluating the clinical
effectiveness of IVIG in this population, there remain
significant uncertainties around the design of a study (with
respect to, for example, the dose or duration of therapy
with IVIG). Without greater understanding of the existing
£0
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Figure 5 Value of further research on IVIG for severe sepsis (and septic shock): population partial EVPI (EVPPI) for groups of uncertain
parameters, according to model for the synthesis of effectiveness evidence (see Table 2 for detailed specification of the models).
IVIG, intravenous immunoglobulin; EVPI, expected value of perfect information; EVPPI, partial EVPI.
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RCT), there is a danger of investing in a large trial that is
suboptimal (for example including a number of different
dosing regimens), which may be a less efficient use of
resources than deferring a definitive trial until we better
understand the existing variation. Thus, our current
recommendations are for research that focuses on filling
the knowledge gaps that exist with a view to informing
the design of a future multicentre RCT. These recommen-
dations include: (i) research on the mechanism(s) of action
of IVIG in severe sepsis (and on understanding the hetero-
geneity of the severe sepsis syndrome) - commencing with
a rigorous review of existing research prior to embarking
on any new studies and; (ii) dose-ranging/finding studies
to identify dose, timing of dose and safety data to inform
the intervention(s).
In addition to clarifying the results on clinical effective-
ness, it may be that research informing other parameters
is also worthwhile, especially with respect to data on theTable 5 Value of further research on IVIG for severe
sepsis/septic shock: ENBS and optimal sample size of a
trial, according to model for the synthesis of
effectiveness evidence (see Table 2 for detailed
specification of the models)
Scenarios for alternative
synthesis models of
effectiveness evidence
Maximum
ENBS
Optimal sample
size per arm (n*)
M1 £ 136,703,882 1900
M2 £ 687,441,146 1200
M3 £ 1,010,953,361 800
M4a £ 605,931,859 900
M4b £ 365,050,246 800
The ENBS provides the societal payoff to the proposed research. It is
computed as the difference between the value of sample information (EVSI)
for a particular research design and the costs of sampling. IVIG, intravenous
immunoglobulin; ENBS: expected net benefit of sampling.longer-term survival and costs of severe sepsis. This
research could be conducted using relatively cheaper,
non-RCT designs, for example using record linkage
between existing databases or conducting a prospect-
ive cohort study providing that the period for which
patients are observed is sufficiently long enough to
capture the impact on costs for several years after the
initial episode.
Conclusions
Our study examined the evidence for the clinical effect-
iveness of IVIG in severe sepsis (including septic shock)
and found significant heterogeneity (variation) between
studies. An in-depth look at the potential sources for the
heterogeneity identified publication bias and dosing regimen
as possible explanatory factors. The rationale for the latter
being a relevant factor was unclear, and for this reason we
examined the implications of the existing heterogeneity
and concluded it affected both the potential clinical and
cost-effectiveness of this treatment and, hence, current
recommendations for its use.
We assessed the value of a new, large, multicentre RCT
to evaluate the clinical and cost-effectiveness of IVIG in
this population and, while our analyses suggest that
such research may be of value, there remains signifi-
cant uncertainties around the design for such a study
(with respect to, for example, the dose or duration of
IVIG). We concluded that, prior to investing in a new
RCT, further research is needed both into the mechanism
(s) of action of IVIG and from a dose-ranging/finding
study.
Our work illustrates the use of an explicit framework
to quantify the value of investing in new research. This
work also highlights that explicit consideration of the
sources of heterogeneity in the current evidence base is
key to informing the design of new research.
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 The effect of IVIG on mortality is associated with a
large degree of heterogeneity between individual
studies. It was unclear what the relevant source of
heterogeneity in the evidence base was.
 The cost-effectiveness of IVIG appears within
the borderline region of estimates considered to
represent value for money in the NHS, but these
results are associated with significant uncertainty
and appear highly sensitive to the alternative
clinical effectiveness models applied.
 Collecting data on the relative effectiveness of IVIG
appears an efficient research design in which to
invest. However, the unclear clinical rationale for the
heterogeneity in the evidence base suggests that,
despite the need for a further RCT, designing this
study will be complex when uncertainties exist at
this level.
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